News Releases


 
News Releases
Date Title and Summary View
Jun 9, 2014 Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the ...
May 1, 2014 CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014. HCV Pipeline Review In Apr...
Apr 30, 2014 CAMBRIDGE, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will host a fireside chat at the Deutsche Bank Securities 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 3:30 p.m. ET at the InterContinental in Boston, MA. Idenix management will also present a co...
Apr 7, 2014 Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437 Idenix on Track to Initiate All-Oral Pan-Genotypic Phase II Combination Clinical Study of IDX21437 and Samatasvir in mid-2014 Idenix Initiates Phase I Clinical Trial of Follow-on Nucleotide Prodrug, IDX21459 Idenix to Host Conference Ca...
Mar 24, 2014 CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, a...
Mar 24, 2014 CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's (the "Court") decision in a patent ...
Mar 14, 2014 Idenix Pharmaceuticals, Inc. / Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Granted European Patent Covering 2'-Methyl-2'-Fluoro Nucleosides for Treating Hep...
Feb 27, 2014 CAMBRIDGE, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the year ended December 31, 2013. HCV Pipeline Review In January...
Feb 26, 2014 CAMBRIDGE, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present at the Cowen & Company 34th Annual Health Care Conference on Wednesday, March 5, 2014, at 8:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA. Management will also present at t...
Feb 7, 2014 CAMBRIDGE, Mass., Feb. 7, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will participate in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 10:45 a.m. Eastern Time at the Waldorf Astoria Hotel in New York, NY. The live...
Page:
1
... NextLast
= add release to Briefcase